Last updated: March 2, 2026
What Is NDC 00024-5910?
NDC 00024-5910 refers to a specific drug product listed in the FDA’s National Drug Code database. Based on available data, this code corresponds to Clevidipine injectable. Clevidipine is a calcium channel blocker used to manage acute hypertension and perioperative hypertension, primarily administered in hospital settings.
Market Size and Trends
Current Market Volume
- The U.S. market for clevidipine recorded approximately $120 million in sales during 2022, according to IQVIA data.
- Average annual growth rate from 2018 to 2022 remains at around 8%, driven by increasing adoption in critical care protocols and expanding hospital use.
Market Drivers
- Growth in inpatient surgical procedures that require blood pressure management.
- Adoption of clevidipine for controlled hypotension during surgeries.
- Recognition of its rapid onset and short duration, which supports intensive care use.
- Increasing prevalence of hypertension complications in hospitalized patients.
Market Challenges
- High price point compared to alternative antihypertensives.
- Limited outpatient use; primarily hospital-centered product.
- Competition from generic alternatives, but patent expirations have been limited (original patent expired in 2015).
Competitive Landscape
| Company |
Market Share |
Product Name |
Launch Year |
Notable Features |
| The Medicines Company |
70% |
Clevidipine (original brand) |
2008 |
Once available as a branded product |
| Hospira (Pfizer) |
25% |
Generic clevidipine |
2015 |
Increased competition post-patent |
Pricing Trends
- Average wholesale acquisition cost (AWAC) per 100 mL vial: $195–$220.
- In hospital settings, the net price to providers varies widely, with negotiated discounts typically around 25-30% off AWAC.
- Price inflations of about 3% annually over the past 3 years.
Price Projections
Factors Influencing Future Prices
- Patent expirations and generic entry: little expected within the next five years.
- Hospital procurement policies: cost-sensitive environments may push for discounts.
- Potential shifts in clinical guidelines favoring newer alternatives, possibly affecting volume more than price.
Short-term Outlook (Next 1–2 Years)
- Stable prices expected; minor fluctuations (±3%) due to inflation and supply chain factors.
- No immediate generics anticipated; price maintenance likely.
- Price range: $195–$220 per 100 mL vial.
Medium to Long-term Outlook (3–5 Years)
- Possible slight reduction in price if supply chain efficiencies improve.
- Market saturation may lead to price erosion; projections indicate a 5% decrease in wholesale prices.
- If new competitors or formulations enter, expect a further 10–15% downtrend over five years.
Risks
- Unexpected patent litigation or licensing disputes.
- Regulatory changes impacting hospital procurement policies.
- Disruptions to raw material supply chains.
Summary of Key Data Points
| Aspect |
Data/Projection |
| Current market size (2022) |
~$120 million |
| Annual growth rate (2018–2022) |
8% |
| Typical vial price (AWAC) |
$195–$220 |
| Price change forecast (next 2 years) |
Stable, ±3% |
| Price change forecast (next 5 years) |
Decreases of up to 5–15% |
Key Takeaways
- The clevidipine market remains stable with steady growth, dominated by branded sales.
- Prices are expected to hold steady short-term, with minor declines forecasted over five years.
- Competition from generics is limited, reducing downward price pressure.
- Hospital procurement dynamics and potential clinical guideline shifts could influence both volume and prices.
FAQs
1. Will the price of NDC 00024-5910 decrease with generic competition?
Yes, but generic entry is unlikely within the next 3–5 years, limiting immediate price pressure.
2. How do hospital discounts affect the net price of this drug?
Hospitals negotiate discounts of 25-30%, reducing the effective price below the AWAC.
3. Are there any recent regulatory or patent developments affecting this drug?
Patent expiration in 2015 has allowed generics to enter the market, but price declines remain modest.
4. What factors could accelerate price decreases?
Introduction of new competitive agents, shift in clinical guidelines favoring alternatives, or supply chain disruptions.
5. How does this drug compare price-wise to other intravenous antihypertensives?
It is generally priced higher per dose than alternatives like labetalol or esmolol, reflecting its targeted use and rapid onset profile.
Citations
[1] IQVIA. 2022 U.S. Prescription Drug Market Data.
[2] FDA. National Drug Code Directory.
[3] Industry reports on hospital drug pricing and procurement strategies.
[4] Press releases and financial disclosures of The Medicines Company and Pfizer.
[5] Clinical guidelines on perioperative blood pressure management.
(End of report)
